600538.SHG Beihai Gofar Marine Biological Industry Co Ltd
- Market cap
- CNY 2.24B
- P/E
- -
- P/B
- 3.48x
- ROE
- -1.5%
- Dividend yield
- 0.01%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600538.SHG undervalued?
Graham numberThe Graham number of Beihai Gofar Marine Biological Industry Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Beihai Gofar Marine Biological Industry Co Ltd fundamental analysis
No fundamental analysis for Beihai Gofar Marine Biological Industry Co Ltd yet.
Beihai Gofar Marine Biological Industry Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Beihai Gofar Marine Biological Industry Co Ltd
Beihai Gofar Chuanshan Biological Co., Ltd., together with its subsidiaries, distributes pharmaceutical products in China. It operates through Pharmaceutical Distribution; Pharmaceutical Manufacturing; DNA Testing Equipment, Consumables and Testing Services; and Others segments. The company wholesales and retails pharmaceutical products through hospitals, clinics, other medical institutions, pharmacies, health centers, clinics, directly operated stores, general agents, distr…
Full company profileBeihai Gofar Marine Biological Industry Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Beihai Gofar Marine Biological Industry Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 263M | 232M | 225M | 251M | 268M | 425M | 460M | 369M | 340M | 328M | 343M |
| Gross Profit | 43.3M | 41.0M | 43.9M | 44.8M | 65.9M | 108M | 127M | 89.7M | 85.8M | 73.7M | 82.1M |
| Operating Income | -13.1M | -12.0M | -20.7M | 9.57M | 8.82M | 15.2M | 42.3M | -77.8M | -91.7M | -23.1M | -5.07M |
| EBITDA | 17.3M | 34.9M | -7.41M | 25.9M | 21.2M | 29.5M | 55.7M | -63.2M | -76.1M | -64.4M | -3.73M |
| Net Income | -31.9M | 8.85M | -21.6M | 5.77M | 3.20M | 10.5M | 34.8M | -82.3M | -93.9M | -87.6M | -9.99M |
| EPS | -0.07 | 0.02 | -0.05 | 0.01 | 0.01 | 0.02 | 0.07 | -0.16 | -0.18 | -0.17 | -0.02 |
| Balance Sheet | |||||||||||
| Total Assets | 958M | 777M | 763M | 750M | 1.07B | 1.08B | 1.14B | 1.06B | 967M | 897M | 865M |
| Total Liabilities | 269M | 118M | 126M | 104M | 214M | 160M | 182M | 176M | 179M | 196M | 199M |
| Shareholders' Equity | 650M | 659M | 638M | 646M | 844M | 917M | 952M | 869M | 775M | 688M | 658M |
| Cash & Short-term Investments | 71.0M | 185M | 114M | 232M | 227M | 190M | 171M | 155M | 145M | 151M | 100M |
| Total Debt | 33.8M | 7.61M | 3.09M | 11.6M | 15.3M | 6.46M | 14.5M | 15.8M | 36.4M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -18.6M | 36.1M | -33.8M | -5.44M | 26.8M | -6.34M | -15.7M | -18.0M | 1.95M | -13.4M | - |
| Capital Expenditure | 11.7M | 15.3M | 26.4M | 4.50M | 1.39M | 23.3M | 7.77M | 10.0M | 10.1M | 6.46M | 4.54M |
| Free Cash Flow | -30.3M | 20.9M | -60.2M | -9.95M | 25.5M | -29.6M | -23.5M | -28.0M | -8.12M | -19.9M | -72.4M |
| Ratios | |||||||||||
| ROE | -4.9% | 1.3% | -3.4% | 0.9% | 0.4% | 1.1% | 3.7% | -9.5% | -12.1% | -12.7% | -1.5% |
| ROA | -3.3% | 1.1% | -2.8% | 0.8% | 0.3% | 1.0% | 3.1% | -7.8% | -9.7% | -9.8% | -1.2% |
| Net Profit Margin | -12.1% | 3.8% | -9.6% | 2.3% | 1.2% | 2.5% | 7.6% | -22.3% | -27.6% | -26.7% | -2.9% |
| Debt to Equity | 0.05x | 0.01x | 0.00x | 0.02x | 0.02x | 0.01x | 0.02x | 0.02x | 0.05x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Beihai Gofar Marine Biological Industry Co Ltd dividends
- Dividend yield
- 0.01%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jul 9, 2003
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 178K | 0.00 | - |
| 2024 | - | - | - |
| 2023 | CNY 16.3K | 0.00 | - |
| 2022 | - | - | - |
| 2021 | CNY 143K | 0.00 | 1.4% |
| 2020 | CNY 143K | 0.00 | 4.5% |
| 2019 | CNY 143K | 0.00 | 2.5% |
| 2018 | CNY 143K | 0.00 | - |
| 2017 | CNY 2.85M | 0.01 | 32.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on Jun 7, 2006.
Who owns Beihai Gofar Marine Biological Industry Co Ltd
- Insiders 19.13%
- Institutions 1.23%
- Public & others 79.65%
- Shares outstanding 524M
- Free float 409M
Beihai Gofar Marine Biological Industry Co Ltd company profile
- Company name
- Beihai Gofar Marine Biological Industry Co Ltd
- Ticker
- 600538.SHG
- ISIN
- CNE000001DD2
- Exchange
- Shanghai Stock Exchange
- Listed since
- Dec 27, 2002
- Sector
- Basic Materials
- Industry
- Chemicals
- Employees
- 438
- Fiscal year end
- December
- Address
- No.3 Beibuwan Middle Road, Beihai, China, 536000
- Phone
- 86 77 9320 0619
- Website
- gofar.com.cn
About Beihai Gofar Marine Biological Industry Co Ltd
Beihai Gofar Chuanshan Biological Co., Ltd., together with its subsidiaries, distributes pharmaceutical products in China. It operates through Pharmaceutical Distribution; Pharmaceutical Manufacturing; DNA Testing Equipment, Consumables and Testing Services; and Others segments. The company wholesales and retails pharmaceutical products through hospitals, clinics, other medical institutions, pharmacies, health centers, clinics, directly operated stores, general agents, distributors, and allocations. It also provides pearl eye drops, pearl powder, and pearl layer powder under the Haibao brand; brand gastrointestinal granules, honeysuckle oral solution, and children's syrup under the Guofa brand; and traumatic injury medicated wine, and sea snake medicated wine under the Haima brand. In addition, the company produces and sells forensic DNA testing equipment, reagents, and consumables; and provides technical services, including DNA testing services. Further, it engages in culture and arts activities; and provision of technical services. The company was formerly known as Beihai Gofar Marine Biological Industry Co., Ltd. and changed its name to Beihai Gofar Chuanshan Biological Co., Ltd. in June 2021. Beihai Gofar Chuanshan Biological Co., Ltd. was incorporated in 1993 and is headquartered in Beihai, China.
Beihai Gofar Marine Biological Industry Co Ltd management
4- Mr. Fang Cai ChengChairman of the Board & President · born 1987
- Mr. Zhi Bo YinCFO, VP & Director · born 1967
- Mr. Yong LiSecretary, VP & Employee Director · born 1965
- Binbin LiAccounting Supervisor